Trial · NCT07214753
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 17 of 17
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number and percentage of patients achieving clinical remission, partial and complete, as per SANI Definition | 24 months | Number and percentage of patient who met the 4 remission criteria (complete or partial) at 12 months and maintained up to 24months |
| Secondary | Number and percentage of patients achieving the criteria for clinical remission | 3, 6, 12 and 24 months | Number and percentage of patient with the criteria for complete or partial remission according to the following criteria: No need to use OCS; Absence of asthma symptoms (ACT score from 20/25 to 25/25); Absence of asthma exacerbations; Stable lung function (FEV1 decline of no more than 100 mL). |
| Secondary | Rate of any and SA exacerbations | 3, 6, 12 and 24 months | annualized exacerbations rate |
| Secondary | Mean change in Asthma Control Test (ACT) score | 1, 3, 6, 12 and 24 months vs baseline | mean (SD) changes (min - max) overtime in ACT score |
| Secondary | Mean changes in Asthma Control Questionnaire (ACQ) score | 1, 3, 6, 12 and 24 months vs baseline | mean (SD) changes (min - max) overtime in ACQ score |
| Secondary | Mean change in FEV1 - pre-BD | 3, 6, 12 and 24 vs baseline | mean (SD) changes in FEV1 (L) overtime |
| Secondary | Mean changes in FEV1 - post-BD | 3, 6, 12 and 24 months vs baseline | mean (SD) changes in FEV1 (L) post-BD |
| Secondary | Mean changes in FEV1 % predicted - pre-BD | 3, 6, 12 and 24 months vs baseline | mean (SD) changes in FEV1 % predicted pre-BD |
| Secondary | Mean changes in FEV1 % predicted - post-BD | 3, 6, 12 and 24 months vs baseline | mean (SD) changes in FEV1 % predicted post-BD |
| Secondary | Mean changes in FVC pre-BD | 3, 6, 12 and 24 months vs baseline | mean (SD) changes in FVC (L) pre-BD |
| Secondary | Mean changes in FVC post-BD | 3, 6, 12 and 24 months vs baseline | mean (SD) changes in FVC (L) post-BD |
| Secondary | Mean changes in pre-BD FEV1/FVC | 3, 6, 12 and 24 months vs baseline | mean (SD) changes in pre-BD FEV1/FVC (ratio) |
| Secondary | Mean changes in pre-BD FEF 25-75 | 3, 6, 12 and 24 months vs baseline | mean (SD) changes in pre\_BD FEF25-75 (L/sec) |
| Secondary | Mean changes in post-BD FEF 25-75 | 3, 6, 12 and 24 months vs baseline | mean (SD) changes in post-BD FEF25-75 (L/sec) |
| Secondary | Mean changes in post-BD FEV1/FVC | 3, 6, 12 and 24 months vs baseline | mean (SD) changes in post-BD FEV1/FVC (ratio) |
| Secondary | Change in inhaled maintenance therapy and inhaled corticosteroid (ICS/LABA/LAMA, ICS/LABA) use and dosage | 3, 6, 12 and 24 months | Change in inhaled maintenance therapy and inhaled corticosteroid (ICS/LABA/LAMA, ICS/LABA) use and dosage after benralizumab treatment |
| Secondary | Change in mOCS use and daily dose | 3, 6, 12 and 24 months | Change in mOCS use and daily dose after benralizumab administartion |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07214753/registered